Tokyo Metropolitan Komagome Hospital   Report issue

Academic/Hospital Phase 2
Founded: Tokyo Japan (1879)

Organization Overview

First Clinical Trial
2006
NCT00270881
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Kiminori Kimura, MD | Komagome Hospital | Komagome Metropolitan Hospital | Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital | Tokyo Metropolitan Komagome Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cholangitis (Phase 1)

Fibrosis (Phase 2)

Hemophilia A (Phase 1)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis C (Phase 2)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Liver Cirrhosis (Phase 2)

Liver Cirrhosis, Biliary (Phase 1)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 11